Another study utilized trastuzumab-conjugated NPs to co-deliver docetaxel and siRNA against HER2 (siHER2), achieving enhanced efficacy in treating HER2+ breast cancer cells and inhibiting tumor growth in a drug-resistant orthotopic mouse model [64]. Here, ERBB2 is linked to breast carcinoma.